Publications

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.PMID:29053779

Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S.Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13.PMID:29030454

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.PMID:29029896

Remyelinating Pharmacotherapies in Multiple Sclerosis.

Bove RM, Green AJ.Neurotherapeutics. 2017 Oct;14(4):894-904. doi: 10.1007/s13311-017-0577-0. Review.PMID:28948533

Systematic integration of biomedical knowledge prioritizes drugs for repurposing.

Himmelstein DS, Lizee A, Hessler C, Brueggeman L, Chen SL, Hadley D, Green A, Khankhanian P, Baranzini SE.Elife. 2017 Sep 22;6. pii: e26726. doi: 10.7554/eLife.26726.PMID:28936969

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.PMID:28920886

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4.

Sagan SA, Cruz-Herranz A, Spencer CM, Ho PP, Steinman L, Green AJ, Sobel RA, Zamvil SS.J Vis Exp. 2017 Aug 21;(126). doi: 10.3791/56185.PMID:28872108

T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury.

Cruz-Herranz A, Sagan SA, Sobel RA, Green AJ, Zamvil SS.J Nat Sci. 2017 May;3(5). pii: e358.PMID:28748216

Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.

Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P, Gelfand JM, Cruz-Herranz A, Cordano C, Alavi MV, Leslie S, Seeley WW, Miller BL, Bigio E, Mesulam MM, Bogyo MS, Mackenzie IR, Staropoli JF, Cotman SL, Huang EJ, Gan L, Green AJ.Sci Transl Med. 2017 Apr 12;9(385). pii: eaah5642. doi: 10.1126/scitranslmed.aah5642.PMID:28404863

Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults.

Casaletto KB, Ward ME, Baker NS, Bettcher BM, Gelfand JM, Li Y, Chen R, Dutt S, Miller B, Kramer JH, Green AJ.Neurobiol Aging. 2017 Mar;51:141-147. doi: 10.1016/j.neurobiolaging.2016.12.011. Epub 2016 Dec 21.PMID:28068565

Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4.

Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS.Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14781-14786. doi: 10.1073/pnas.1617859114. Epub 2016 Dec 8.PMID:27940915

Neurologic Complications of Common Variable Immunodeficiency.

Nguyen JT, Green A, Wilson MR, DeRisi JL, Gundling K.J Clin Immunol. 2016 Nov;36(8):793-800. Epub 2016 Oct 4.PMID:27704236

Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery.

Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, Pekarek K, A Sagan S, Xiao L, Teuscher C, von Büdingen HC, Wess J, Lawrence JJ, Green AJ, Fancy SP, Zamvil SS, Chan JR.Elife. 2016 Sep 27;5. pii: e18246. doi: 10.7554/eLife.18246.PMID:27671734

Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination.

Mei F, Mayoral SR, Nobuta H, Wang F, Desponts C, Lorrain DS, Xiao L, Green AJ, Rowitch D, Whistler J, Chan JR.J Neurosci. 2016 Jul 27;36(30):7925-35. doi: 10.1523/JNEUROSCI.1493-16.2016.PMID:27466337

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.PMID:27464262

Sex differences and subclinical retinal injury in pediatric-onset MS.

Graves JS, Chohan H, Cedars B, Arnow S, Yiu H, Waubant E, Green A.Mult Scler. 2017 Mar;23(3):447-455. doi: 10.1177/1352458516652497. Epub 2016 Jul 11.PMID:27306618

The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium.Neurology. 2016 Jun 14;86(24):2303-9. doi: 10.1212/WNL.0000000000002774. Epub 2016 May 25.PMID:27225223

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.

Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ.J Neurol. 2016 Jul;263(7):1323-31. doi: 10.1007/s00415-016-8127-y. Epub 2016 May 3.PMID:27142714

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.PMID:27011339

Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis.

Chahin S, Miller D, Sakai RE, Wilson JA, Frohman T, Markowitz C, Jacobs D, Green A, Calabresi PA, Frohman EM, Galetta SL, Balcer LJ. Mult Scler Relat Disord. 2015 Jul;4(4):304-10. doi: 10.1016/j.msard.2015.05.005. Epub 2015 May 21.

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG. JAMA Neurol. 2015 Aug;72(8):897-904. doi: 10.1001/jamaneurol.2015.0993.

Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.

Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, Jin C, Green AJ, McCulloch CE, Pelletier D, Waubant E. Mult Scler Relat Disord. 2014 Nov;3(6):720-7. doi: 10.1016/j.msard.2014.07.003. Epub 2014 Jul 23.

The best basic science paper in MS in 2013: Antimuscarinic therapies in remyelination.

Green AJ. Mult Scler. 2014 Dec;20(14):1814-6. doi: 10.1177/1352458514558679. Epub 2014 Nov 12.

Retinal damage and vision loss in African American multiple sclerosis patients.

Kimbrough DJ, Sotirchos ES, Wilson JA, Al-Louzi O, Conger A, Conger D, Frohman TC, Saidha S, Green AJ, Frohman EM, Balcer LJ, Calabresi PA. Ann Neurol. 2015 Feb;77(2):228-36. doi: 10.1002/ana.24308. Epub 2015 Jan 13.

Encephalitis of unclear origin diagnosed by brain biopsy: a diagnostic challenge.

Gelfand JM, Genrich G, Green AJ, Tihan T, Cree BA. JAMA Neurol. 2015 Jan;72(1):66-72. doi: 10.1001/jamaneurol.2014.2376.

A randomized controlled phase II trial of riluzole in early multiple sclerosis.

Waubant E, Maghzi AH, Revirajan N, Spain R, Julian L, Mowry EM, Marcus J, Liu S, Jin C, Green A, McCulloch CE, Pelletier D. Ann Clin Transl Neurol. 2014 May;1(5):340-7. doi: 10.1002/acn3.60. Epub 2014 Apr 14.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen. 

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14.

Focal Amyotrophy in Multiple Sclerosis

Malik R, Irodenko V, Zimmerman L, Green A, Layzer R.
Muscle Nerve. 2014 Sep 3. Doi: 10.1002/mus24439

Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD.

Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfnad JM, Minami S, Boscardin J, Martens LH, Seely WW, Yu G, Herz J, Filiano AJ, Arrant AE, Roberson ED, Kraft TW, Farese RV Jr,  Green A, Gan L.
J Exp Med. 2014 Aug 25. pii: jem.20140214

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.

Mei F, Fancy SP, Shen YA, Niu J, Zhao C, Presley B, Miao E, Lee S, Mayoral SR, Redmond SA, Etxeberia A, Franklin RJ, Green A, Hauser SL, Chan JR. 
Nat Med. 2014 Aug;20(8):954-60. doi: 10.1038. Epub 2014 Jul 6

Reply: Microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface.

Green, AJ, Schwartz, D., Gelfand, J. 
Brain. 2013 Nov; 136(Pt 11):e261

Point-of-care ocular ultrasound to detect optc disc swelling.

Teismann N, Lenaghan P, Nolan R, Stein J, Green, A. 
Acad Emerg Med. 2013 Sep;20(9):920-5. doi:10.1111/acem.12206

Optic nerve head component responses of the multifocal electroretinogram in MS.

Frohman TC, Beh SC, Saidha S, Schnurman Z, Conger D, Conger A, Ratchford JN, Lopez C,
Galetta SL, Calabresi PA, Balcer LJ, Green AJ, Frohman EM. 
Neurology. 2013 Aug 6; 81(6):545-5

Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica.

Gelfand JM, Cree VA, Nolan R, Arnow S, Green AJ
JAMA Neurol. 2013 Mar 25; 1-5

Reply: Microcystic macular degeneration from optic neuropathy: not inflammatory, not trans-synaptic degeneration.

Gelfand JM, Green AJ. 
Brain. 2013 Jul; 136(Pt 7):e240.

Getting beyond the ganglion cell: morphometric adjustments for retinal optical coherence tomography in multiple sclerosis.

Green AJ.
JAMA Neurol. 2013 Jan 1; 70(1):13-5.

Fingolimod treatment in multiple sclerosis leads to increased macular volume.

Nolan R, Gelfand JM, Green AJ.
Neurology. 2013 Jan 8; 80(2):139-44.

Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, Ratchford JN, Oh J, Seigo MA, Newsome SD, Balcer LJ, Frohman EM, Green AJ, Nguyen QD, Calabresi PA. 
Lancet Neurol. 2012 Nov; 11(11):963-72.

Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes.

Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. 
PLoS One. 2012; 7(5):e36847.

Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. 
Brain. 2012 Jun; 135(Pt 6):1786-93.

The OSCAR-IB consensus criteria for retinal OCT quality assessment.

Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A. 
PLoS One. 2012; 7(4):e34823.

Color vision is strongly associated with retinal thinning in multiple sclerosis.

Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A. 
Mult Scler. 2012 Jul; 18(7):991-9.

Will the real optic nerve sheath please stand up?

Teismann NA, Lenaghan P, Stein J, Green A. 
J Ultrasound Med. 2012 Jan; 31(1):130-1.

Vitamin D in African Americans with multiple sclerosis.

Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM,
Miller JW, Hauser SL, Green AJ. 
Neurology. 2011 May 24; 76(21):1824-30.

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ,
Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. 
PLoS One. 2011; 6(2):e16664.

MR imaging of optic neuropathy with extended echo-train acquisition fluid-attenuated inversion recovery.

Aiken AH, Mukherjee P, Green AJ, Glastonbury CM. 
AJNR Am J Neuroradiol. 2011 Feb; 32(2):301-5.

Heterogeneous patterns of tissue injury in NARP syndrome.

Gelfand JM, Duncan JL, Racine CA, Gillum LA, Chin CT, Zhang Y, Zhang Q,
Wong LJ, Roorda A, Green AJ. 
J Neurol. 2011 Mar; 258(3):440-8.

Optical coherence tomography: a sign of the times.

Green AJ. 
Neurology. 2010 Oct 12; 75(15):1312-3.

Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. 
Lancet Neurol. 2010 Sep; 9(9):921-32.

Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.

Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R. 
Brain. 2010 Jun; 133(Pt 6):1591-601.

Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis.

Green AJ, Cree BA. 
J Neurol Neurosurg Psychiatry. 2009 Sep; 80(9):1002-5.

Understanding pseudo: the symptoms are real, the cause is unclear.

Green AJ. 
Neurology. 2009 May 12; 72(19):1626-7.

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.

Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL,
Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ,
Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H,
Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL,
Kappos L, Polman CH, Oksenberg JR.
Hum Mol Genet. 2009 Feb 15; 18(4):767-78.

Suprasellar germinoma and late perioptic seeding.

Pereira LS, Green AJ, Hwang TN, McCulley TJ. 
Eur J Ophthalmol. 2008 Jan-Feb; 18(1):159-61.

Pediatric multiple sclerosis.

Chabas D, Green AJ, Waubant E. 
NeuroRx. 2006 Apr; 3(2):264-75.

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. 
N Engl J Med. 2005 Jul 28; 353(4):375-81.

Post-traumatic epidermoid cyst presenting with headache.

Green AJ, Roberts DR, Swanson RA. 
Neurology. 2005 May 10; 64(9):1657.

Genetic basis for clinical expression in multiple sclerosis.

Barcellos LF, Oksenberg JR, Green AJ, Bucher P, Rimmler JB,
Schmidt S,n Garcia ME, Lincoln RR, Pericak-Vance MA, Haines JL,
Hauser SL. 
Brain. 2002 Jan; 125(Pt 1):150-8.

Multiple sclerosis and oligodendroglioma.

Green AJ, Bollen AW, Berger MS, Oksenberg JR, Hauser SL. 
Mult Scler. 2001 Aug; 7(4):269-73.

Sequence variation in the transforming growth factor-beta1 (TGFB1) gene and multiple sclerosis susceptibility.

Green AJ, Barcellos LF, Rimmler JB, Garcia ME, Caillier S, Lincoln RR, Bucher P, Pericak-Vance MA, Haines JL, Hauser SL,
Oksenberg JR. 
J Neuroimmunol. 2001 May 1; 116(1):116-24.